ONCOLYTICS BIOTECH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.47 CAD | -1.34% |
|
+2.08% | -17.88% |
| Apr. 11 | Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA | CI |
| Apr. 11 | Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 162.1 | 130.8 | 96.3 | 131 | 132.3 | 110.9 | - | - |
| Enterprise Value (EV) 1 | 162.1 | 130.8 | 96.3 | 131 | 132.3 | 110.9 | 110.9 | 110.9 |
| P/E ratio | -4.1 x | -5.39 x | -3.57 x | -5.16 x | -4.37 x | -3.31 x | -3.34 x | -44.5 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 129 x | 16.6 x | 2.94 x |
| EV / Revenue | - | - | - | - | - | 129 x | 16.6 x | 2.94 x |
| EV / EBITDA | -7.88 x | -5.23 x | -3.69 x | -4.94 x | -3.96 x | -2.64 x | -1.94 x | -1.26 x |
| EV / FCF | - | -5.92 x | -4.24 x | -5.6 x | -4.65 x | -1.88 x | -1.68 x | -1.4 x |
| FCF Yield | - | -16.9% | -23.6% | -17.9% | -21.5% | -53.1% | -59.4% | -71.7% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 26,358 | 43,319 | 55,027 | 59,029 | 73,914 | 75,420 | - | - |
| Reference price 2 | 6.150 | 3.020 | 1.750 | 2.220 | 1.790 | 1.470 | 1.470 | 1.470 |
| Announcement Date | 3/5/20 | 3/5/21 | 3/3/22 | 3/3/23 | 3/7/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 0.8571 | 6.676 | 37.74 |
| EBITDA 1 | -20.57 | -25.01 | -26.1 | -26.53 | -33.39 | -41.95 | -57.1 | -88.2 |
| EBIT 1 | -20.69 | -26.12 | -26.23 | -26.92 | -33.79 | -39.17 | -46.18 | -26.2 |
| Operating Margin | - | - | - | - | - | -4,570.42% | -691.7% | -69.44% |
| Earnings before Tax (EBT) 1 | -33.12 | -22.51 | -26.25 | -24.75 | -27.66 | -36.23 | -45.83 | -26.17 |
| Net income 1 | -33.1 | -22.51 | -26.3 | -24.84 | -27.75 | -36.23 | -40.94 | -20.35 |
| Net margin | - | - | - | - | - | -4,226.81% | -613.26% | -53.93% |
| EPS 2 | -1.500 | -0.5600 | -0.4900 | -0.4300 | -0.4100 | -0.4438 | -0.4397 | -0.0330 |
| Free Cash Flow 1 | - | -22.1 | -22.72 | -23.41 | -28.46 | -58.9 | -65.85 | -79.45 |
| FCF margin | - | - | - | - | - | -6,871.69% | -986.37% | -210.54% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 3/5/21 | 3/3/22 | 3/3/23 | 3/7/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.5 | - |
| EBITDA 1 | -6.07 | -7.432 | -6.213 | -5.949 | -5.962 | -8.409 | -6.637 | -7.064 | -10.94 | -8.742 | -8.9 | -9.9 | -11 | -14.1 | - |
| EBIT 1 | -6.155 | -7.455 | -6.31 | -6.046 | -6.06 | -8.508 | -6.734 | -7.16 | -11.05 | -8.849 | -8.81 | -9.306 | -9.931 | -11.16 | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | -744.05% | - |
| Earnings before Tax (EBT) 1 | -4.865 | -7.709 | -6.779 | -5.07 | -4.405 | -8.498 | -6.437 | -7.394 | -9.918 | -3.906 | -8.516 | -8.982 | -9.595 | -9.162 | - |
| Net income 1 | -4.777 | -7.751 | -6.779 | -5.095 | -4.407 | -8.554 | -6.437 | -7.441 | -9.925 | -3.949 | -8.516 | -8.982 | -9.595 | -9.162 | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | -610.82% | - |
| EPS 2 | -0.0900 | -0.1400 | -0.1200 | -0.0900 | -0.0800 | -0.1500 | -0.1000 | -0.1200 | -0.1400 | -0.0500 | -0.1122 | -0.1110 | -0.1150 | -0.1016 | -0.1200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/5/21 | 3/3/22 | 5/5/22 | 8/11/22 | 11/7/22 | 3/3/23 | 5/5/23 | 8/14/23 | 11/3/23 | 3/7/24 | - | - | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -22.1 | -22.7 | -23.4 | -28.5 | -58.9 | -65.9 | -79.5 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | -0.5500 | -0.4200 | -0.4000 | -0.4200 | -0.4000 | - | - |
| Capex 1 | 0.01 | 0.03 | 0.29 | 0.06 | 0.01 | 0.5 | 0.5 | 5.5 |
| Capex / Sales | - | - | - | - | - | 58.33% | 7.49% | 14.57% |
| Announcement Date | 3/5/20 | 3/5/21 | 3/3/22 | 3/3/23 | 3/7/24 | - | - | - |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.47
CAD
Average target price
5.833
CAD
Spread / Average Target
+296.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.88% | 80.99M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ONC Stock
- Financials Oncolytics Biotech Inc.
